danuglipron oral GLP-1
Selected indexed studies
- Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. (Metabolism, 2023) [PMID:37852529]
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. (Endocr Rev, 2026) [PMID:41054801]
- Oral GLP-1 Receptor Agonists for Weight Loss. (Cardiol Rev, 2024) [PMID:39688941]
_Worker-drafted node — pending editorial review._
Connections
danuglipron oral GLP-1 is a side effect of
Sources
- Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. (2021) pubmed
- Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. (2023) pubmed
- A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. (2022) pubmed
- Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes. (2023) pubmed
- Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis. (2023) pubmed
- Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial. (2023) pubmed
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. (2026) pubmed
- "Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024). (2025) pubmed
- Oral GLP-1 Receptor Agonists for Weight Loss. (2024) pubmed
- A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus. (2023) pubmed